EIP
SRNE

Ellis Investment Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Ellis Investment Partners’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50
Closed – – 842
2021
Q3 		$0 Hold
50
– – ﹤0.01% 815
2021
Q2 		$0 Hold
50
– – ﹤0.01% 803
2021
Q1 		$0 Hold
50
– – ﹤0.01% 797
2020
Q4 		$0 Hold
50
– – ﹤0.01% 803
2020
Q3 		$0 Buy
+50
New +$458 ﹤0.01% 758

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ellis Investment Partners's SRNE Position: Q4 2021 in Review

Ellis Investment Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2021, closing a stake of 50 shares.

Ellis Investment Partners first reported a position in SRNE in Q3 2020 and held it in 5 quarters. The position peaked at $0 in Q3 2021. 234 funds tracked by Wall St. Rank hold SRNE as of Q4 2021.

  • Ellis Investment Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Ellis Investment Partners sold 50 Sorrento Therapeutics, Inc. shares in Q4 2021.
  • Ellis Investment Partners first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 5 quarters.
  • Ellis Investment Partners's Sorrento Therapeutics, Inc. position peaked at $0 in Q3 2021.
  • 234 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2021.

Based on Ellis Investment Partners's 13F filing for Q4 2021, filed 1 Feb 2022.